News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ust

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and P...

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patien

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Resul...

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results fr

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, ...

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Pat...

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of D...

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-A

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interch...

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangea

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574)...

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Anti
See all news items
Previous
Next

Discover the world of Teva

Follow our latest feature stories with news and views from across our global organization

Discover more Discover the world of Teva

Media Resources

Media Inquiries

Contact our corporate communications.

Learn more Media Inquiries

Media Kit

Files and resources for media use only

Download Teva Media Kit Media Kit

Financial Reports

View Teva financial news on our global website.

Learn more Financial Reports

Connect with us

Teva Social Media Guidelines.

Learn more Connect with us